SS
DNTH icon

SBI Securities’s Dianthus Therapeutics DNTH Stock Holding History

SBI Securities’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97 Sell
1
-20
-95% -$1.75K ﹤0.01% 3520
2026
Q1 		$1.76K Buy
21
+19
+950% +$1.1K ﹤0.01% 2461
2025
Q4 		$82 Hold
2
– – ﹤0.01% 3464
2025
Q3 		$79 Buy
2
+1
+100% +$26 ﹤0.01% 3585
2025
Q2 		$19 Hold
1
– – ﹤0.01% 3922
2025
Q1 		$18 Sell
1
-6
-86% -$132 ﹤0.01% 3871
2024
Q4 		$153 Buy
+7
New +$180 ﹤0.01% 3331

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

SBI Securities's DNTH Position: Q2 2026 in Review

SBI Securities reduced its Dianthus Therapeutics (DNTH) stake by 95% in Q2 2026, selling an estimated $1.75K and leaving 1 share worth $97. The position accounts for ﹤0.01% of the portfolio, ranked #3520.

SBI Securities first reported a position in DNTH in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.76K in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • SBI Securities held 1 share of Dianthus Therapeutics worth $97 as of Q2 2026.
  • SBI Securities sold 20 Dianthus Therapeutics shares in Q2 2026, an estimated $1.75K.
  • Dianthus Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3520 holding.
  • SBI Securities first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Dianthus Therapeutics position peaked at $1.76K in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.